These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24697134)

  • 1. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200.
    Yalcin AD; Genc GE; Celik B; Gumuslu S
    Clin Lab; 2014; 60(3):523-4. PubMed ID: 24697134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab therapy for bullous pemphigoid.
    Yu KK; Crew AB; Messingham KA; Fairley JA; Woodley DT
    J Am Acad Dermatol; 2014 Sep; 71(3):468-74. PubMed ID: 24954907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful management of severe infant bullous pemphigoid with omalizumab.
    Dufour C; Souillet AL; Chaneliere C; Jouen F; Bodemer C; Jullien D; Cambazard F; Joly P; Reix P
    Br J Dermatol; 2012 May; 166(5):1140-2. PubMed ID: 22098309
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum soluble CD200 level was higher in patients with bullous pemphigoid during the active phase of the disease than for healthy individuals.
    Akman-Karakaş A; Yalcin AD; Koç S; Gumuslu S; Ergun E; Genc GE; Ongut G; Uzun S; Alpsoy E
    Clin Lab; 2014; 60(7):1237-40. PubMed ID: 25134396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of bullous pemphigoid with omalizumab.
    London VA; Kim GH; Fairley JA; Woodley DT
    Arch Dermatol; 2012 Nov; 148(11):1241-3. PubMed ID: 23165827
    [No Abstract]   [Full Text] [Related]  

  • 7. [EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].
    Neumark M; Tal Y; Zlotogorski A; Molho-Pessach V
    Harefuah; 2020 Jan; 159(1):29-30. PubMed ID: 31930804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels.
    Yalcin AD; Cilli A; Bisgin A; Strauss LG; Herth F
    Expert Opin Biol Ther; 2013 Sep; 13(9):1335-41. PubMed ID: 23883435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary: Omalizumab therapy for bullous pemphigoid by KK Yu, AB Crew, KAN Messingham, JA Fairley, DT Woodley. J Am Acad Dermatol 2014 Jun 20. pii: S0190-9622(14)01410-8. doi: 10.1016/j.jaad.2014.04.053. [Epub ahead of print].
    Yancey KB
    Dermatol Ther; 2015; 28(1):3. PubMed ID: 25286315
    [No Abstract]   [Full Text] [Related]  

  • 10. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
    James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
    Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.
    Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V
    Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin E and bullous pemphigoid.
    Cozzani E; Gasparini G; Di Zenzo G; Parodi A
    Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dermatological implications of omalizumab, an anti-IgE antibody].
    Di Lucca-Chrisment J
    Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature.
    Balakirski G; Alkhateeb A; Merk HF; Leverkus M; Megahed M
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1778-1782. PubMed ID: 27357866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up.
    Yalcin AD; Uçar S; Gumuslu S; Strauss LG
    Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):524-7. PubMed ID: 23841472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab in the treatment of bullous pemphigoid: A single-center series of 15 cases.
    Altan Ferhatoglu Z; Yucesoy SN; Ak T; Demir Y
    Medicine (Baltimore); 2024 Jul; 103(30):e38684. PubMed ID: 39058846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma.
    Yalcin AD; Bisgin A; Cetinkaya R; Yildirim M; Gorczynski RM
    Clin Lab; 2013; 59(1-2):71-7. PubMed ID: 23505909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating atopic asthma with the anti-IgE monoclonal antibody.
    D'Amato G
    Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
    Ujiie H
    J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.